不同剂量奥曲肽在重症急性胰腺炎治疗中的效果与安全性比较

Efficacy and security of different doses of octreotide in the treatment of severe acute pancreatitis

目的比较不同剂量奥曲肽在重症急性胰腺炎治疗中的临床疗效和安全性。方法回顾性分析我院收治的68例重症急性胰腺炎患者的临床资料,所有患者均给予奥曲肽治疗,将患者根据不同剂量奥曲肽分为常规剂量组和加倍剂量组,分别给予0.6mg/d和1.2mg/d奥曲肽治疗,比较两组患者的临床疗效和发症发生情况及病死率。结果治疗后常规剂量组的总有效率为85.29%,显著低于加倍剂量组患者的总有效率94.12%(P<0.05);常规剂量组和加倍剂量组的并发症发生率均为8.82%(P>0.05),常规剂量组的病死率为8.82%,加倍剂量组的病死率为2.94%,两组差异有统计学意义(P<0.05)。结论 1.2mg/d剂量奥曲肽治疗重症急性胰腺炎临床效果显著,安全性高。

Objective Comparison of different doses of octreotide in the treatment of severe acute pancreatitis in clinical efficacy and safety.Methods A retrospective analysis of our hospital,68 patients with severe acute pancreatitis patients with clinical data,all patients were treated with octreotide treatment,patients were divided into conventional-dose group and doubling dose group according to the different doses of octreotide were given 0.6mg/d and 1.2mg/d octreotide two groups were compared the clinical efficacy and complications and mortality.Results After treatment,the conventional-dose group total effective rate was 85.29%,the doubling dose group was significantly lower than patients overall efficiency of 94.12%（P0.05）;conventional-dose group and doubling dose group complication rate was 8.82%,no significant difference（P0.05）,the conventional dose group,the mortality rate was 8.82%,the doubling dose group the mortality rate was 2.94%,a significant difference between the two groups（P0.05）.Conclusion 1.2mg/d dose of octreotide treatment of severe acute pancreatitis significant clinical effect and safety.